CTX310 Cuts Triglycerides 63% at Day 30, Beating Analyst Expectations
CRSP is trading near its 52-week low of $44.12 (3.1% above the low).
Summary
CRISPR presented Phase 1b data at AHA showing a single course of CTX310 cut mean triglycerides 63% and ANGPTL3 65% at Day 30 in 10 patients with severe hypertriglyceridemia, with median baseline triglycerides above 1,000 mg/dL. The fuller dataset adds a 51% mean drop in non-HDL-C, 23% in ApoB and 16% in LDL-C, and reductions persisted in patients followed at least 90 days. Safety was clean: no serious adverse events, no Grade 3 or higher treatment-related events, no clinically relevant liver enzyme elevations, and zero acute pancreatitis cases even though 30% of enrollees had prior history. William Blair said the 63% triglyceride reduction beat its roughly 50% expectation and reiterated Outperform, noting RMAT designations in sHTG and elevated LDL-C give the program preliminary regulatory buy-in. Despite that, shares fell 8.17% to $45.95, near the 52-week low of $44.12 — the market is not paying for the data. Additional Phase 1b cohorts are still recruiting.
At the time of this announcement, CRSP was trading at $45.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $44.12 to $63.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.